Ozanezumab
NOGO-A is a protein that in humans is encoded by the RTN4 gene that has been identified as an inhibitor of neurite outgrowth specific to the central nervous system.From an announced phase II clinical trial by GSK:[2]NOGO-A blocks neurons from growing toward muscle once the connection has been made.When motor neurons degenerate and the connection becomes weakened, NOGO-A would work against keeping that nerve/muscle contact strong.Thus, it is hoped that it will preserve muscle function and slow the rate of ALS progression in humans.[3][4] The antibodies in our body work by binding to foreign material (such as bacteria and viruses) so that it is no longer dangerous and can be 'labelled for destruction' for white blood cells.